AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

AstraZeneca Divests Rights of its Nexium and Vimovo Product to Grunenthal

Shots:

  • AZ will receive an upfront $700M & $115M plus milestone payments up to $90M & $17M for Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) respectively. Grunenthal to get commercialization rights for Nexium in EU & WW rights for Vimovo (except in the US & Japan)
  • AZ will continue to manufacture and supply Nexium under the long-term supply agreement having its global commercialization rights except in EU
  • Nexium a proton pump inhibitor indicated for gastroesophageal reflux disease, ulcers, and Zollinger-Ellison syndrome & Vimovo is a FD combination drug of naproxen, for OA, RA & AS having net sales $121M in EU & $37M WW (except the US & Japan) respectively
  • In 2012 & 2013, Pfizer Consumer Health & Horizon Pharma gained rights for Nexium (over-the-counter) & Vimovo (in the US) from AZ respectively

Click here to read full press release/ article | Ref: AstraZeneca| Image: Pharmacy Business